ABEO on Nasdaq
ABEONA THERAPEUTICS INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Heat Biologics, Korro Bio, Inc. or KYNTRA BIO, INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-1536.9%Operating margin3
1223.1%Net margin3
44.7%Return on equity3
0.05×Debt to equity3
-$84.3MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
License brought in 58% of the revenue ABEONA THERAPEUTICS INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2025 |
|---|---|
| License | $3.4M |
| Product | $2.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue1¢$1.5M
- Research and development16¢$26.8M
- Selling, general and admin39¢$65.0M
- Interest2¢$3.7M
- Income tax0¢$100.0K
- Profit42¢$71.2M
Out of $5.8M in revenue.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenues | $5.8M | |
| Cost of sales | $1.5M | |
| Royalties | $1.9M | |
| Research and development | $26.8M | $34.4M |
| Selling, general and administrative | $65.0M | $29.9M |
| Total costs and expenses | $95.3M | $64.2M |
| Loss from operations | -$89.4M | -$64.2M |
| Interest income | $5.6M | $4.2M |
| Interest expense | -$3.7M | -$4.2M |
| Change in fair value of warrant and derivative liabilities | $6.1M | -$755.0K |
| Gain from sale of priority review voucher, net | $152.4M | |
| Other income, net | $410.0K | $1.2M |
| Income (loss) before income taxes | $71.3M | -$63.7M |
| Income tax (benefit) expense | $100.0K | |
| Net income (loss) | $71.2M | -$63.7M |
| Basic income (loss) per common share | $1.34 | -$1.55 |
| Dilutive income (loss) per common share | $1.01 | -$1.55 |
| Basic | 53.0M shares | 41.0M shares |
| Dilutive | 66.1M shares | 41.0M shares |
| Change in unrealized gains related to available-for-sale debt securities | $130.0K | $74.0K |
| Comprehensive income (loss) | $71.3M | -$63.7M |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $78.4M | $23.4M | |
| Short-term investments | $113.0M | $74.4M | |
| Restricted cash | $338.0K | ||
| Accounts receivable, net | $6.1M | ||
| Inventory | $5.5M | ||
| Other receivables | $568.0K | $1.7M | |
| Prepaid expenses and other current assets | $1.3M | $1.1M | |
| Total current assets | $204.9M | $100.9M | |
| Property and equipment, net | $9.9M | $4.4M | |
| Operating lease right-of-use assets | $4.0M | $3.6M | |
| Other assets | $781.0K | $96.0K | |
| Total assets | $219.6M | $108.9M | |
| Accounts payable | $7.9M | $3.4M | |
| Accrued expenses | $8.5M | $6.3M | |
| Current portion of long-term debt | $12.2M | $5.9M | |
| Current portion of operating lease liability | $864.0K | $823.0K | |
| Accrued taxes | $126.0K | ||
| Other current liabilities | $2.0K | $64.0K | |
| Total current liabilities | $29.6M | $16.6M | |
| Long-term operating lease liabilities | $4.1M | $3.3M | |
| Long-term debt | $7.8M | $13.0M | |
| Warrant liabilities | $18.9M | $32.0M | |
| Total liabilities | $60.4M | $64.9M | |
| Common stock - $0.01 par value; authorized 200,000,000 shares; 55,043,413 and 45,644,091 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $550.0K | $457.0K | |
| Additional paid-in capital | $900.6M | $856.8M | |
| Accumulated deficit | -$742.1M | -$813.3M | |
| Accumulated other comprehensive loss | $138.0K | $8.0K | |
| Total stockholders equity | $159.2M | $44.0M | $14.8M |
| Total liabilities and stockholders equity | $219.6M | $108.9M | |
| Preferred stock, par value | $0.01 | $0.01 | |
| Preferred stock, shares authorized | 2.0M shares | 2.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.01 | $0.01 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 55.0M shares | 45.6M shares | |
| Common stock, shares outstanding | 55.0M shares | 45.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) | $71.2M | -$63.7M |
| Depreciation and amortization | $2.5M | $2.0M |
| Stock-based compensation expense | $10.8M | $6.6M |
| Change in fair value of warrant and derivative liabilities | -$6.1M | $755.0K |
| Accretion and interest on short-term investments | $889.0K | $276.0K |
| Amortization of right-of-use lease assets | $1.0M | $903.0K |
| Non-cash interest | $1.2M | $1.5M |
| Gain on disposal of property and equipment | -$2.0K | |
| Gain from sale of priority review voucher | -$152.4M | |
| Accounts receivable | -$6.1M | |
| Inventory | -$5.5M | |
| Other receivables | $1.1M | $792.0K |
| Prepaid expenses and other current assets | -$151.0K | -$564.0K |
| Other assets | -$685.0K | $181.0K |
| Accounts payable and accrued expenses | $6.5M | $1.5M |
| Accrued taxes | $126.0K | |
| Lease liabilities | -$576.0K | -$1.3M |
| Change in payable to licensor | -$5.0M | |
| Other current liabilities | -$85.0K | $16.0K |
| Net cash used in operating activities | -$76.3M | -$56.0M |
| Proceeds from sale of priority review voucher, net of transaction costs of $2.6 million | $152.4M | |
| Capital expenditures | -$8.0M | -$2.4M |
| Proceeds from disposal of property and equipment | $18.0K | |
| Purchases of short-term investments | -$206.6M | -$157.0M |
| Proceeds from maturities of short-term investments | $167.3M | $120.2M |
| Net cash provided by (used in) investing activities | $105.0M | -$39.2M |
| Proceeds from ATM sales of common stock, net of issuance costs | $17.3M | $15.5M |
| Payments related to net settlement of restricted share awards | -$37.0K | -$526.0K |
| Proceeds from underwritten sales of common stock, net of issuance costs | $70.2M | |
| Proceeds from exercise of warrants | $8.8M | |
| Proceeds from issuance of long-term debt | $20.0M | |
| Payment of debt issuance costs | -$963.0K | |
| Net cash provided by financing activities | $26.0M | $104.1M |
| Net increase in cash, cash equivalents and restricted cash | $54.7M | $8.9M |
| Right-of-use asset obtained in exchange for new operating lease liabilities | $1.4M | |
| Derivative and warrant additions associated with loan and security agreement | $80.0K | $1.0M |
| Reclassification of derivative and warrant liability to equity | $7.1M | $1.1M |
| Changes in accrued property and equipment | -$406.0K | $471.0K |
| Cash paid for interest | $2.6M | $2.7M |
| Cash paid for taxes | $7.0K |
Former names
Recent filings
- Sep 29, 2026144
- Sep 29, 2026144
- Sep 29, 2026144
- Sep 29, 2026144
- Sep 29, 20264
- Sep 29, 20264
- Sep 29, 20264
- Sep 29, 20264
- Sep 15, 20268-K
- Sep 1, 2026144
- Sep 1, 20264
- Aug 14, 2026SCHEDULE 13G/A
- Aug 13, 20268-K
- Aug 13, 202610-Q
- Jul 22, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10